Athish K, Nayak Rao S, Marimuthu V, Krishna V, Arun A
Cureus. 2024; 16(6):e61562.
PMID: 38962632
PMC: 11220731.
DOI: 10.7759/cureus.61562.
Odhiambo F, Nareeba S, Mwangeka G, Njambi A, Nyakebati V
Clin Case Rep. 2024; 12(6):e8889.
PMID: 38799537
PMC: 11126650.
DOI: 10.1002/ccr3.8889.
Ottaru T, Kwesigabo G, Butt Z, Caputo M, Chillo P, Siril H
Healthcare (Basel). 2024; 12(6).
PMID: 38540623
PMC: 10970453.
DOI: 10.3390/healthcare12060657.
Rivera A, Pak K, Mefford M, Hechter R
Open Forum Infect Dis. 2024; 11(2):ofad695.
PMID: 38352151
PMC: 10863550.
DOI: 10.1093/ofid/ofad695.
Cervantes C, Atta M
Curr HIV/AIDS Rep. 2023; 20(2):100-110.
PMID: 36695948
DOI: 10.1007/s11904-023-00645-1.
HIV, drugs and the kidney.
Wearne N, Davidson B, Blockman M, Swart A, Jones E
Drugs Context. 2020; 9.
PMID: 32256631
PMC: 7104683.
DOI: 10.7573/dic.2019-11-1.
Changes in kidney function among men having sex with men starting on demand tenofovir disoproxil fumarate - emtricitabine for HIV pre-exposure prophylaxis.
Liegeon G, Antoni G, Pialoux G, Capitant C, Cotte L, Charreau I
J Int AIDS Soc. 2020; 23(2):e25420.
PMID: 32086878
PMC: 7035456.
DOI: 10.1002/jia2.25420.
Kidney Disease in HIV Infection.
Alfano G, Cappelli G, Fontana F, Di Lullo L, Di Iorio B, Bellasi A
J Clin Med. 2019; 8(8).
PMID: 31430930
PMC: 6722524.
DOI: 10.3390/jcm8081254.
Reversal of tenofovir induced nephrotoxicity: case reports of two patients.
Some F, Koech M, Chesire E, Kigen G
Pan Afr Med J. 2017; 27:126.
PMID: 28904656
PMC: 5567942.
DOI: 10.11604/pamj.2017.27.126.10033.
Refining criteria for selecting candidates for a safe lopinavir/ritonavir or darunavir/ritonavir monotherapy in HIV-infected virologically suppressed patients.
Gianotti N, Cozzi-Lepri A, Antinori A, Castagna A, De Luca A, Celesia B
PLoS One. 2017; 12(2):e0171611.
PMID: 28192453
PMC: 5305227.
DOI: 10.1371/journal.pone.0171611.
Update on current management of chronic kidney disease in patients with HIV infection.
Diana N, Naicker S
Int J Nephrol Renovasc Dis. 2016; 9:223-234.
PMID: 27695357
PMC: 5033612.
DOI: 10.2147/IJNRD.S93887.
Risk of Chronic Kidney Disease among Patients Developing Mild Renal Impairment during Tenofovir-Containing Antiretroviral Treatment.
Lapadula G, Bernasconi D, Casari S, Maggiolo F, Cauda R, Di Pietro M
PLoS One. 2016; 11(9):e0162320.
PMID: 27632369
PMC: 5025011.
DOI: 10.1371/journal.pone.0162320.
Effects of a switch from tenofovir- to abacavir-based antiretroviral therapy, with or without atazanavir, on renal function.
Guillemi S, Ling S, Dahlby J, Yip B, Zhang W, Hull M
J Int AIDS Soc. 2016; 19(1):20995.
PMID: 27624144
PMC: 5022114.
DOI: 10.7448/IAS.19.1.20995.
Renal Dysfunction during Tenofovir Use in a Regional Cohort of HIV-Infected Individuals in the Asia-Pacific.
Tanuma J, Jiamsakul A, Makane A, Avihingsanon A, Ng O, Kiertiburanakul S
PLoS One. 2016; 11(8):e0161562.
PMID: 27560968
PMC: 4999237.
DOI: 10.1371/journal.pone.0161562.
Tenofovir-associated nephrotoxicity in patients with chronic hepatitis B: two cases.
Cho H, Cho Y, Cho E, Lee J, Yu S, Oh K
Clin Mol Hepatol. 2016; 22(2):286-91.
PMID: 27377911
PMC: 4946401.
DOI: 10.3350/cmh.2015.0066.
Reversibility of Glomerular Renal Function Decline in HIV-Uninfected Men and Women Discontinuing Emtricitabine-Tenofovir Disoproxil Fumarate Pre-Exposure Prophylaxis.
Mugwanya K, Wyatt C, Celum C, Donnell D, Kiarie J, Ronald A
J Acquir Immune Defic Syndr. 2016; 71(4):374-80.
PMID: 26914909
PMC: 4770857.
DOI: 10.1097/QAI.0000000000000868.
Is Abnormal Urine Protein/Osmolality Ratio Associated with Abnormal Renal Function in Patients Receiving Tenofovir Disoproxil Fumarate?.
Marcelin J, Berg M, Tan E, Amer H, Cummins N, Rizza S
PLoS One. 2016; 11(2):e0149562.
PMID: 26872144
PMC: 4752319.
DOI: 10.1371/journal.pone.0149562.
Long-Term Follow-Up of Proteinuria and Estimated Glomerular Filtration Rate in HIV-Infected Patients with Tubular Proteinuria.
Peyriere H, Cournil A, Casanova M, Badiou S, Cristol J, Reynes J
PLoS One. 2015; 10(11):e0142491.
PMID: 26571117
PMC: 4646508.
DOI: 10.1371/journal.pone.0142491.
Higher tenofovir exposure is associated with longitudinal declines in kidney function in women living with HIV.
Baxi S, Scherzer R, Greenblatt R, Minkoff H, Sharma A, Cohen M
AIDS. 2015; 30(4):609-18.
PMID: 26558723
PMC: 4782771.
DOI: 10.1097/QAD.0000000000000958.
Urine alpha1-microglobulin is a better marker for early tubular dysfunction than beta2-microglobulin among tenofovir-exposed human immunodeficiency virus-infected men who have sex with men.
Kang J, Liu J, Ding H, Li X, Wang Q, Guo X
Braz J Infect Dis. 2015; 19(4):410-6.
PMID: 26119851
PMC: 9427450.
DOI: 10.1016/j.bjid.2015.05.004.